ICLUSIG®

Drug Information Related Patent

Hold Company

TAKEDA PHARMS USA

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 15MG BASE; EQ 45MG BASE; EQ 30MG BASE; EQ 10MG BASE

Indication

ICLUSIG® is indicated in adult patients with chronic myeloid leukemia (CML) that is resistant or intolerant to at least two kinase inhibitors. It is used in accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome-positive acute lymphoblastic leukemia without other kinase inhibitors for indications. It can also be used for positive T315l CML (chronic stage, accelerating or explosion) or T315l positive Ph + ALL.

Use

Instructions for Use

API

PONATINIB HYDROCHLORIDE

API Structure

We Supply

PONATINIB HYDROCHLORIDE

Note:

Facility GMP
USMF/HC MF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
11192895	2033/12/12
11192897	2033/12/12
11384086	2033/12/12
8114874	2027/1/24
9029533	2026/12/22
9493470	2033/12/12

API Patent

Patent No	Expiration Date
8114874	2027/1/24
9029533	2026/12/22

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION